GSK sets foot in bioelectronics

August 4, 2016 News BioVox

GSK and Verily, a company from the internet giant Alphabet, will invest 640 million in bioelectronics. With tiny implants, the size of a grain of rice, organs can be triggered, which could help to control diseases.

Bioelectronics are the new hype in healthcare. It is a huge step forward that GSK, a company in the health sector, and Verily, a technological company, join hands.

GSK and Verily work on treatments for diabetes, rheumatism and arthritis. Within ten years, there should be a treatment on the market. Other solutions, such as obesity and infertility, will be examined later.

In Belgium, IMEC in Leuven also works on bioelectronics. It designed an electronic chip that can bridge the gap between biological tissue and brains. However it still is a prototype, the possibilities seem very exciting and endless!

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter